“It is with mixed emotions that I leave my role as the Chief Scientific Officer, however, I am excited to continue providing scientific guidance to Advaxis as we progress toward clinical validation of the platform in furtherance of Advaxis’ mission to improve the lives of people with cancer.”
9 years of nothing, but failures from the Chief Scientific Officer, who stopped buying shares a long time back.
News 
Market Data 
Discover 
